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Abstract
Progranulin (PGRN) is a pleiotropic protein that has gained the attention of the neuroscience
community with recent discoveries of mutations in the gene for PGRN that cause frontotemporal
lobar degeneration (FTLD). Pathogenic mutations in PGRN result in null alleles, and the disease is
likely the result of haploinsufficiency. Little is known about the normal function of PGRN in the
central nervous system apart from a role in brain development. It is expressed by microglia and
neurons. In the periphery, PGRN is involved in wound repair and inflammation. High PGRN
expression has been associated with more aggressive growth of various tumors. The properties of
full length PGRN are distinct from those of proteolytically derived peptides, referred to as granulins
(GRNs). While PGRN has trophic properties, GRNs are more akin to inflammatory mediators
such as cytokines. Loss of the neurotrophic properties of PGRN may play a role in selective
neuronal degeneration in FTLD, but neuroinflammation may also be important. Gene expression
studies suggest that PGRN  is up-regulated in a variety of neuroinflammatory conditions, and
increased PGRN expression by microglia may play a pivotal role in the response to brain injury,
neuroinflammation and neurodegeneration.
Background
Progranulin (PGRN) was discovered independently by
several investigators and given several different names,
including granulin-epithelin precursor, proepithelin,
prostate cancer (PC) cell derived growth factor and acro-
granin [1]. Encoded by a single gene on chromosome
17q21 (PGRN), PGRN is a 593-amino acid, cysteine-rich
protein with an estimated molecular weight of 68.5 kDa
that runs at 90 kDa on standard western blots due to
heavy glycosylation [2]. It contains seven granulin-like
domains, which consist of highly conserved tandem
repeats of a rare 12 cysteinyl motif [3,4] (Figure 1). Prote-
olytic cleavage of the precursor protein by extracellular
proteases, such as elastase, gives rise to smaller peptide
fragments termed granulins (GRNs) or epithelins [1].
These fragments range in size from 6 to 25 kDa and have
been implicated in a range of biological functions [1,5].
Previous work on PGRN focused on its role in embryonic
development and neoplasia (reviewed elsewhere [1]). The
recent discovery that mutations in PGRN cause frontotem-
poral lobar degeneration with ubiquitin-immunoreactive
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neuronal inclusions (FTLD-U) has brought renewed inter-
est in PGRN and its functions in the central nervous sys-
tem (CNS). We review what is known about PGRN in
peripheral tissues during injury, repair and inflammation
and explore the relevance of these properties to CNS dis-
orders, with a focus on FTLD-U.
PGRN in the periphery
Gene expression studies
Basal gene expression studies in mice and rats reveal wide-
spread expression of PGRN in many different tissues, as
well as in epithelial and hematopoietic cell lines [6,7].
Expression of PGRN mRNA is particularly high in epithe-
lial cells that have a rapid turnover, such as those of the
skin and gastrointestinal tract. Non-proliferating epithe-
lia, such as lung alveolar cells, have relatively low levels of
expression [6]. Epididymal cells have high PGRN expres-
sion, but are mitogenically stable, implying a pleiotropic
role for PGRN. Mesenchymal tissues that lack PGRN
mRNA are mitogenically responsive to PGRN in vitro.
Both full length PGRN [1] and its proteolytic peptides [8]
have mitogenic affects on epithelial cells in culture. Many
transformed or immortalized epithelial cell lines express
PGRN [3], while primary cells and cells in vivo have rela-
tively low PGRN expression [6].
PGRN peptides were originally isolated and characterized
in activated leukocytes [9]. In the periphery PGRN mRNA
is abundant in lymphoid tissue of the lung, gut and
spleen, and expression is also high in hematopoietic cell
lines [6]. Hematopoietic myeloid cells, such as macro-
phages and tissue histiocytes in liver, spleen, lungs and
brain, show no labeling by in situ hybridization even
though a profile of human macrophages transcripts in
vitro identified PGRN as one of the most highly expressed
mRNAs [10]. All in vitro results suggests that there are high
levels of expression in hematopoietic myeloid cells in the
periphery, but low basal level of expression in vivo. In con-
trast to the mitogenic properties of PGRN on epithelial
cells, there is little evidence to suggest that PGRN has
mitogenic effects on hematopoietic cells [6,11].
PGRN in wound healing
PGRN is an important growth factor in the wound healing
response [12], which can be separated into the distinct
phases of inflammation, epithelialization, granulation,
neovascularization and contraction (reviewed in [13]). In
experimental skin wounds of mice, PGRN  mRNA
increases in fibroblasts, endothelial cells, macrophages
and neutrophils. Fibroblasts and endothelial cells have no
PGRN expression in normal skin, but there is constitutive
expression of PGRN in keratinocytes. Addition of PGRN
to the wound increases and prolongs infiltration of neu-
trophils and macrophages, and it enhances neovasculari-
zation [12], but it has no effect on the overall rate of
healing [14]. The role of PGRN in the later stages of
wound healing is minimal. Stimulation of fibroblasts and
endothelial cells in vitro with PGRN causes proliferation
and migration, suggesting that injury-induced expression
of PGRN may have a paracrine effect. Supporting this
hypothesis, PGRN was shown to have the same properties
as known stimulators of neovascularization, such as vas-
cular endothelial growth factor, in a cell culture model
[12].
PGRN and inflammation
The wound repair response also sheds light on the roles of
PGRN and GRNs during inflammation. Zhu and cowork-
ers demonstrated an immunoregulatory role of PGRN and
GRN peptides during wound healing and highlighted
novel interactions between PGRN, secretory leukocyte
protease inhibitor (SLPI) and elastase. SLPI is a 14-kDa
protein encoded by a gene on chromosome 20 in a
genomic region that has several genes with protease inhib-
itor domains [15] that has been implicated in regulating
proteolysis. It is produced by macrophages and neu-
trophils and is known to inhibit the inflammatory
response of these cells to various agents [16]. Elastase, a
serine proteinase released in large quantities by neu-
trophils during inflammation, acts on PGRN to generate
GRN peptides by cleaving short linker regions between
the different GRN domains [14]. Interestingly, SLPI can
inhibit this process by binding directly to the linker
regions on PGRN as well as to elastase, thereby acting as a
potent regulator of PGRN proteolytic processing.
The protein sequence of full length PGRN and its proteolyti- cally cleaved GRNs Figure 1
The protein sequence of full length PGRN and its proteolyti-
cally cleaved GRNs. Amino acids shown in bold represent 
the granulin consensus sequence separated by variably long 
linker regions. Cysteine-rich parts of the sequence are 
denoted by CC.Journal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
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The role of elastase and SLPI in regulating inflammation
can be recognized by the contrasting effects of PGRN and
GRN on epithelial cells and neutrophils. In cell culture,
GRN(B) stimulates epithelial cells to secrete interleukin-8
(IL-8), a major chemoattractant for neutrophils and
monocytes, whereas PGRN has no such effect. In response
to proinflammatory cytokines, such as tumor necrosis fac-
tor alpha (TNFα), neutrophils adhere, spread, undergo
degranulation and release a range of reactive species
(including elastase) during respiratory burst. PGRN inhib-
its spreading, degranulation and respiratory burst of
TNFα-activated neutrophils. In contrast, GRN (A) and
GRN (B) peptides have no inhibitory effect. These obser-
vations implicate pro-inflammatory and anti-inflamma-
tory roles for GRN and PGRN, respectively.
Although PGRN can inhibit TNFα-mediated neutrophil
activation, it has no effect on neutrophils already under-
going a respiratory burst. This phenomena has also been
seen when using reagents that disrupt signaling events
that lead to the respiratory burst [17,18], suggesting
PGRN somehow changes intracellular signaling events
after TNFα binds to one of the TNF receptors [14]. In light
of this, it is not surprising that wounds in SLPI deficient
mice have increased leukocyte infiltration and elevated
elastase activity, as well as impaired wound healing [19].
Addition of recombinant SLPI or PGRN to these animals
normalizes wound response [14], suggesting that PGRN
was being converted into GRNs as a result of unregulated
proteolysis by elastase in wounds of SLPI-deficient mice.
Deficiency in SLPI has the potential to disrupt the ratio of
PGRN to GRNs resulting in excess GRNs and a net pro-
inflammatory response. Collectively, these results suggest
that activities of elastase (generating GRNs) and SLPI
(inhibiting PGRN cleavage) are biological regulators of
the innate immune response during wound healing.
Cytokines and hormones act as regulators of PGRN
expression. Proinflammatory cytokines of the innate
immune system, interleukin1 beta (IL-1β) and TNFα, acti-
vate PGRN gene expression in murine embryo fibroblasts
[20]. The promoter for both human [21] and murine
[22]PGRN contain regulatory elements that are involved
in cytokine and growth-factor – regulated gene expres-
sion, including IL-6 response factor [21]. There is also
increased expression of PGRN  in inflammatory and
immune disorders, such as rheumatoid arthritis [23], a
zebra fish model of chronic tuberculosis [24] and a
murine model simulating chemokine-induced alveolar
monocyte trafficking [25]. PGRN is preferentially associ-
ated with cells of the innate immune system, including
macrophages and neutrophils. IL-4, which is an anti-
inflammatory cytokine of the adaptive immune system,
decreases PGRN expression in certain myeloid cells [11].
Together these studies suggest a pleiotropic role for PGRN
during inflammation in peripheral tissues.
PGRN in the CNS
Gene expression in the CNS
Few studies have investigated the expression and function
of PGRN in the CNS. Initial studies analyzing brain
homogenates by northern blot analysis reported relatively
low levels of expression of PGRN mRNA in the brain [7].
Using  in situ hybridization techniques in adult rodent
brains, PGRN mRNA was found to be abundant in specific
neuronal subsets, including cortical pyramidal neurons,
cerebellar Purkinje cells and pyramidal neurons of the
hippocampus [6]. Immunohistochemical studies have
also shown expression of PGRN in certain neuronal pop-
ulations (Figure 2) [26,27]. The subcellular location of
PGRN in neurons is currently unknown, but preliminary
studies suggest that it may be associated with endosomal
or lysosomal vacuoles.
During CNS development [2]PGRN expression is high in
neuroepithelial cells in the embryo and then decreases in
fetal development, where it is restricted to the forebrain,
olfactory lobes, retinal ganglion and spinal cord. Later,
PGRN is expressed throughout the neocortex, but not in
regions where neurogenesis is known to occur, such as the
subventricular zone [28]. The differential expression of
PGRN in specific cell types during forebrain development
suggests a role in the developing CNS.
Neurotrophic properties of PGRN
PGRN promotes growth of PC12 cells, a pheochromocy-
toma-derived neuronal cell line that responds poorly to
most nerve growth factors [6]. The only other growth fac-
tors shown to have an effect on PC12 cells similar to
PGRN are insulin growth factors-1 and 2 (IGF-1 and IGF-
2). In embryonic fibroblasts PGRN activates similar signal
transduction pathways as IGF-1 and IGF-2. [29]. Although
these results suggest a neurotrophic role for PGRN, there
are subtle, but potentially important, differences between
PGRN and other growth factors. For example, in a blunt-
force traumatic brain injury model in mice, most growth
factors, such as neuregulin and brain derived neuro-
trophic factor, show robust increases in as few as three
hours. In the same model, increases in PGRN mRNA do
not occur until 24 hours, by which time the expression of
the other growth factors have returned to normal [30].
The delayed induction of PGRN and its potential roles in
normal and pathological conditions requires further
investigation, but the available evidence suggests that
PGRN may be important in long-term neuronal survival,
but not a significant factor in response to acute neuronal
injuries.Journal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
Page 4 of 13
(page number not for citation purposes)
Microglial expression of PGRN
Non-neuronal cell types also show evidence of PGRN
expression in the CNS. Although initial in situ hybridiza-
tion studies of PGRN expression did not detect any signal
in glial cells [6], more recent immunohistochemical stud-
ies have shown strong immunoreactivity in microglia
[26,27,31] (Figure 2), especially when activated. Micro-
glia are intrinsic CNS glial cells derived from the mononu-
clear phagocyte system [32,33], which fits with the fact
that PGRN is a protein produced by hematopoietic cell
types [6,7,11]. In contrast, astrocytes and oligodendroglia,
which are derived from the neural tube, have no or very
low levels of PGRN immunoreactivity [27].
Microglia represent about 5–20% of all CNS glia [32,33].
Current evidence suggests that microglia are derived from
monocytes that enter the developing brain during embry-
ogenesis, after which they differentiate into resident
microglia [34]. There is little turnover of resident micro-
glia, but more so for perivascular macrophages [35].
Under normal conditions microglia are quiescent and
characterized morphologically by ramified processes and
a small soma. In response to pathologic insults, such as
traumatic injury, infection or neurodegeneration, micro-
glia become activated. In the activated state microglia
have proliferative potential, and they undergo migration
and phagocytosis [36,37]. During injury-induced micro-
Immunohistochemical staining of human brain tissue using a PGRN-specific polyclonal antibody Figure 2
Immunohistochemical staining of human brain tissue using a PGRN-specific polyclonal antibody. In a neurologically normal indi-
vidual, PGRN immunoreactivity is present in hippocampal pyramidal neurons, but particularly high in CA1 (A), dentate fascia 
(B) and endplate/CA4 (C). In AD, neurons and activated microglia (arrows) in the endplate are labeled (D), along with PGRN 
immunoreactivity associated with dystrophic neurites in senile plaques (inset).Journal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
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glial activation, increases in microglia occurs through
both mitosis of resident microglia [38] and migration of
bone-marrow derived cells into the CNS [39-41].
Microglial activation is associated with changes in shape
and functional properties, including increases in cell sur-
face molecules (e.g., HLA-DR and β2-integrins) and pro-
duction of proinflammatory cytokines (e.g., IL-1β and
TNFα), chemokines, growth factors and inflammatory
mediators (e.g., platelet activation factor) [42]. In most
conditions, microglial activation is accompanied by reac-
tive astrocytic gliosis [43]. Together these features are the
face of neuroinflammation, the major response of the
innate immune system in the CNS.
In the context of neurodegenerative diseases, sustained
microglial activation has been linked to neuronal injury
and loss, in part mediated by excessive production of
proinflammatory cytokines and other toxic species [44-
46]. According to this theory, neuronal injury occurs
through a "by-stander" mechanism [47]. Considering the
role of PGRN during inflammation in the periphery,
along with the mechanism by which microglia respond,
tight regulation of PGRN expression in the CNS would
seem important. A model of ischemic stroke in rats [48]
provides a theoretical means by which PGRN may be reg-
ulated during CNS inflammation (Figure 3). Microglia
and astrocytes both respond to hypoxic-ischemic neuro-
nal injury with abundant cross-talk between these cell
populations. For example, IL-1β is produced by activated
microglia and is a major activator of astrocytes [49]. Con-
versely, colony stimulating factor 1 (CSF-1) and granulo-
cyte-macrophage colony stimulating factor are potent
microglial growth factors that are produced by activated
astrocytes [50,51]. Interestingly, astrocytes also express
SLPI, the elastase- and PGRN-binding protein implicated
as a regulator of PGRN proteolysis in the periphery [14],
during ischemic stroke where it reduces ischemic-induced
injury [48]. It remains to be shown whether SLPI regulates
PGRN proteolysis in the CNS. As noted above, in the
periphery the relative balance between the activities of
elastase and SLPI influences the levels of the anti-inflam-
matory PGRN and the pro-inflammatory GRNs. It is
worth noting that cultured microglia have been shown to
produce elastase [52], which is also thought to be a key
player in this inflammatory switch mechanism. Environ-
mental or genetic factors that may affect the normal regu-
lation of PGRN could have adverse consequences leading
to neuroinflammation and neurodegeneration.
Although the neurotoxic potential of chronically activated
microglia has been the focus of most studies, a growing
body of research suggests that microglia may play a neu-
roprotective role, as well [53]. This has prompted some
researchers to suggest that the loss of normal physiologic
functions of microglia may contribute to neurodegenera-
tion. Since PGRN has been shown to have trophic func-
tions in the periphery, and it is expressed by activated
microglia, it is intriguing to speculate that microglia-
derived PGRN may support neuronal viability or possibly
perform a role equivalent to wound healing in the periph-
ery mediated by its neurotrophic activity. There are several
lines of evidence that lend support to this hypothesis.
First, microglia have the ability to produce neurotrophic
factors, such as thrombospondin [53,54]. Second, micro-
glia produce other growth factors, such as TGF-β, during
injury and repair [55,56]. Third, as mentioned previously,
PGRN has growth factor properties on neuronal cells in
culture [6]. Obviously, much remains to be learned about
potential neurotrophic properties of microglia-derived
PGRN as it relates to neurodegeneration.
PGRN in CNS disorders and animal models of 
CNS disease
Much of the available information on PGRN expression in
various disorders comes from unbiased expression array
studies in which PGRN  was shown to be one of the
responsive genes increased compared to controls. Interest-
ingly, almost all the mRNA expression studies that have
shown differential expression of PGRN share the common
property of microglial activation and inflammation, lead-
ing some researchers to speculate that the increase in
PGRN expression is closely related to microglial activation
and neuroinflammation [1].
PGRN in models of CNS viral infection
PGRN has been shown to be increased in young mice dur-
ing the host response to two different strains of Sindbis
virus with varying neurovirulence [57]. Virus replication,
viral burden and evidence of apoptosis were greater with
the more virulent strain, even though neuronal cell tro-
pism was the same. Histologic evidence of inflammation
was mild, but the gene expression profile highlighted dif-
ferences between virulent and non-virulent strains. In par-
ticular, a number of chemokine genes, as well as PGRN,
that are up-regulated in microglia during inflammation
were increased during infection by the virulent strain.
Given that both microglia and neurons expressed PGRN,
it is not possible to know the cellular origin of the PGRN
in this and other models.
PGRN in models of Creutzfeldt-Jakob disease (CJD)
Studies of the gene expression profile of microglial cell
cultures taken from mice infected with CJD (M-CJD) have
provided some information on the microglial expression
of PGRN in response to different activating stimuli [58].
The pathogenic prion protein has been shown to accumu-
late in activated microglia, although the mechanism for
this remains to be determined [59]. Proinflammatory
transcripts, such as IL-1β and complement factors, as wellJournal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
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as PGRN were increased in M-CJD. When normal micro-
glia were challenged with endotoxin (LPS) and interferon-
gamma (IFNγ), to mimic the expression profile of acti-
vated microglia, PGRN expression was substantially sup-
pressed compared to that seen in M-CJD. In addition,
both IL1β and TNFα were highly expressed in M-CJD and
LPS treated mice, but PGRN was only increased in MCJD.
This paradoxical response of PGRN may relate to the plei-
otropic functional properties of PGRN not expected with
more traditional growth factors; PGRN may function as a
growth factor or anti-inflammatory agent as an intact mol-
ecule, but as a source of diverse inflammatory mediators,
when it undergoes proteolysis to GRNs. The only other
transcripts that had an expression pattern similar to PGRN
were LY5, leukocytes common antigen and CD84, which
are involved in inflammation and intracellular communi-
cation [58]. These particular studies suggest that micro-
glial expression of PGRN increases during
neuroinflammation in neurodegenerative disease, but not
during simple microglial induction through LPS treat-
ment. As a result, fundamental questions need to be
addressed concerning the role of PGRN in microglial
function. In particular, it is not known if PGRN is differ-
entially expressed by intrinsic microglia or by bone-mar-
row derived macrophages.
PGRN in models of lysosomal storage disease
Mucopolysaccharidoses (MPS) type I and type IIIB are lys-
osomal storage diseases that affect the CNS. Mouse mod-
els have suggested that activated microglia accelerate the
neuronal degeneration caused by lysosomal storage [60].
Microarray gene analysis of cortical brain tissue from
Hypothetical interaction between PGRN, elastase and SLPI in the CNS Figure 3
Hypothetical interaction between PGRN, elastase and SLPI in the CNS. 1) PGRN expression in neurons in the absence of 
microglial-derived elastase has potentially growth factor and anti-inflammatory properties. 2) In response to CNS injury, 
microglia are activated and release inflammatory mediators, including proteases. 3) PGRN and elastase levels increase, resulting 
in the proteolytic cleavage of PGRN into GRNs, which may contribute to the inflammatory milieu. 4) Inflammatory signals such 
as IL-1β derived from activated microglia cause changes in nearby cells. 5) Astrocytes become reactive in response to inflam-
matory stimulus from activated microglia. 6) Reactive astrocytes produce SLPI, which along with its other anti-inflammatory 
properties, inhibits the proteolytic cleavage of PGRN into GRN as a means of feedback regulation of the inflammatory 
response.Journal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
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these mouse models showed a prominent inflammatory
pattern of gene expression, which was accompanied by
increases in PGRN  [61]. They also demonstrated that
microglia in these mice contain massive lysosomal vacu-
oles. It remains to be determined if the increase in PGRN
in these models is due to neuronal degeneration or to
microglial activation in response to abnormal lysosomal
storage.
PGRN in ALS
PGRN  mRNA expression in ALS spinal cord has been
found to be increased by 400% compared with controls
[62]. This is likely related to microglial activation, which
has been implicated in the pathogenesis of ALS [63]. As
discussed later, the neuronal cytoplasmic inclusions in
motor neurons of ALS are composed of the same protein
(TDP-43) as those in FTLD-U [64,65], which suggests a
fundamental linkage between ALS and FTLD.
PGRN in Alzheimer's disease (AD)
Several recent studies have shown PGRN immunoreactiv-
ity in AD is associated with amyloid plaques [31] (Figure
2), including labeling of microglia and dystrophic neur-
ites [27]. Plaque-related dystrophic neurites are large
axonal varicosities that are associated with reduced den-
dritic spine density and shaft diameter [66]. Considering
that  PGRN  expression is increased during injury and
repair in the periphery, the presence of PGRN immunore-
activity in dystrophic neurites could reflect a reparative
response in damaged axons. Complementing this hypoth-
esis is the observation that dystrophic neurites are con-
stantly being formed and resolved; however, the rate of
dystrophic neurite formation exceeds their resolution
[66]. Considering the growth factor properties of PGRN in
the periphery, it is tempting to speculate that PGRN may
be involved in neuritic remodeling.
Most studies have shown PGRN to be present in the peri-
karya of neurons, but it is unknown whether PGRN is also
normally present in axons or dendrites. If PGRN is nor-
mally present in axons, then the accumulation of PGRN in
dystrophic neurites may also reflect disruption of axonal
transport, similar to what is found for other axonally
transported proteins such as amyloid precursor protein
[67].
PGRN in FTLD-U
Mutations in PGRN cause FTLD-U
Recent interest in PGRN has been fueled by the discovery
of mutations in PGRN in some families with autosomal
dominant FTLD-U [27,31,68-70]. Prior to this discovery,
no mutations in PGRN  had been associated with any
human disorder [1]. FTLD-U is a member of a diverse
group of neurodegenerative disorders that produce fron-
totemporal dementia, which accounts for 5–15% of all
dementia disorders [71]. The clinical phenotype in
patients with PGRN mutations is similar to those with
sporadic frontotemporal dementia. They have a variable
age of onset, and the dementia tends to be characterized
by prominent behavioral and language dysfunction, usu-
ally a progressive non-fluent aphasia [72]. Mild parkin-
sonism is common, but motor neuron disease is usually
absent [26,73].
Mutations in the gene for the microtubule associated pro-
tein tau (MAPT) on chromosome 17q21, which inciden-
tally is in close proximity to the PGRN gene, are known to
be responsible for 10–20% of familial frontotemporal
dementia [74]. These cases are pathologically character-
ized by the abnormal accumulation of hyperphosphor-
ylated tau protein in neurons and glia, which is distinct
from the FTLD-U pathology in PGRN-related frontotem-
poral dementia. To date no MAPT mutations have been
detected in FTLD-U [75].
A recent study reported the frequency of PGRN mutations
in FTLD to be 5% in a patient referral series, which is a
similar frequency to that of MAPT mutations in the same
series of patients [69]. At least 35 different pathogenic
PGRN mutations have now been identified, all of which
are predicted to create functional null alleles with the
majority causing premature termination of the coding
sequence [69]. The introduction of a premature termina-
tion codon results in degradation of the mutant mRNA
species by nonsense mediated decay [31]. As a result, there
is no production of mutant protein. It therefore appears
that PGRN mutations cause FTLD-U due to a partial loss
of functional PGRN, (haploinsufficiency), rather than
accumulation of mutant protein characteristic of fronto-
temporal dementia due to MAPT mutations.
Several other genes or chromosomal loci have been iden-
tified for FTLD-U, including mutations in the gene for val-
osin-containing protein (VCP) [76] and CHMP2b
(charged multivesicular body protein 2b) [77]. VCP is an
endoplasmic reticulum-associated protein that is involved
in ER-stress related protein degradation [78,79]. While lit-
tle is known about CHMP2b, it appears to play a role in
endosomal trafficking through the ESCRT (endosomal
secretory complex required for trafficking) III complex,
which may be involved in degradation of growth factors
[80]. Given the preliminary evidence that PGRN is a neu-
rotrophic factor that may be associated with endosomal
or lysosomal vacuoles, it raises the intriguing possibility
that the three major genes for FTLD-U are associated with
defects in protein degradation linked to membranous
cytoplasmic organelles.
FTLD-U is the most common pathology associated with
frontotemporal dementia and is characterized by focalJournal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
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cortical atrophy with spongiosis, gliosis and ubiquitin-
immunoreactive neuronal cytoplasmic inclusions (NCI)
and neurites in layer II of affected cortices and in the hip-
pocampal dentate fascia [81] (Figure 4). Most cases also
have neuronal loss in the hippocampus consistent with
hippocampal sclerosis [82]. In postmortem series, pathol-
ogy was more severe and associated with marked neuro-
nal loss and gliosis in cases with PGRN  mutations
compared to those without mutations [73]. The presence
of lentiform shaped neuronal intranuclear inclusions
(NII) is a consistent feature of cases with PGRN muta-
tions, but is not entirely specific [83,84] (Figure 4).
As in any neurodegenerative disorder neuronal loss in
FTLD-U is accompanied by reactive astrogliosis and
microglial activation (Figure 4). There are no studies of
microglial functional properties in FTLD-U cases with and
without PGRN mutations. A closer look at the inflamma-
tory response in cases with and without the PGRN muta-
tion would also be helpful in understanding the
biological role of PGRN in FTLD-U.
Neuronal inclusions in FTLD-U contain TDP-43
Consistent with the haploinsufficiency mechanism, NCI
and NII in familial FTLD-U with PGRN mutations do not
contain mutant PGRN [26]. A major component of the
inclusion bodies was recently shown to be TAR DNA
binding protein-43 (TDP-43) [64,65] (Figure 4). The
same protein was also found to be present in the neuronal
inclusions in ALS. Very little is known about the biological
function of TDP-43. Originally identified as a ubiqui-
tously expressed 43-kDa protein, TDP-43 binds to the TAR
DNA in the long terminal repeat region of human immu-
nodeficiency virus (HIV)-1, resulting in repression of pro-
moter activity [85]. It was also independently identified as
a regulator of alternative splicing of exon 9 of the cystic
fibrosis transmembrane conductance regulator transcript,
through its ability to bind (UG)n-repeated RNA sequences
[86]. It is thought that these DNA and RNA binding prop-
erties implicate TDP-43 as a transcription regulator
through one of its two RNA-recognition motifs [85,87].
TDP-43 is widely expressed in many tissues, including the
brain [85], where immunohistochemistry highlights dif-
fuse, but grainy expression of nuclei of neurons and other
CNS cells. In FTLD-U, the normal nuclear staining pattern
is absent in neurons that contain NCI and NII, leading
investigators to suggest that TDP-43 is translocated from
the nucleus to the cytoplasm [64] or that TDP-43 is pre-
vented from crossing the nuclear membrane possibly, as a
result of hyperphosphorylation of TD-43 [88]. This
abnormal metabolism of TDP-43 in the FTLD-U seems
central to the disease pathogenesis given that the gene
encoding TDP-43 is highly conserved among different
species [89] consistent with an essential, yet currently
unknown biological function.
TDP-43 and PGRN
The relationship between PGRN and TDP-43 and their
respective roles in neurodegeneration is currently
unknown. Although most of the biological considerations
in this review have focused on PGRN as a secreted protein;
there is data suggesting an intracellular and possibly even
an intra-nuclear role for PGRN. While most growth factors
function through binding to cell surface receptors with
subsequent intracellular signaling, there is recent evidence
to suggest that some growth factors or inflammatory
mediators may cross the cell membrane through currently
poorly defined means to gain access to the cytosol and
even the nucleus (reviewed in [90]). It is intriguing to
speculate that PGRN may be involved in intracellular traf-
ficking. There is little experimental evidence to support
this hypothesis at present, but studies of transcriptional
regulation hint at a possible link between PGRN and TDP-
43. In these studies intracellular trafficking of certain pro-
teins has been shown to be modulated differentially by
PGRN and GRN. PGRN and one of the GRN peptides,
CDE, have the ability to bind cyclin T1 [91], an essential
protein component of the positive transcription elonga-
tion factor needed to phosphorylate the largest subunit of
RNA polymerase II, resulting in transcriptional elongation
(reviewed by [92]). When PGRN and cyclin T1 are co-
expressed in the same cell, both are restricted to cyto-
plasm, thereby inhibiting transcription elongation [91].
In contrast, when co-expressed with GRN (CDE), both
proteins are localized mainly in the nucleus. Given these
results and the abnormal location of TDP-43 in the cyto-
plasm rather than the nucleus in FTLDU, it raises the pos-
sibility that PGRN might be involved in the trafficking of
TDP-43. Interestingly, PGRN is known to bind HIV-1 and
HIV-2 tat proteins [91,93]. Tat proteins associate with TAR
DNA, a property that is also shared by TDP-43 [85]. If
TDP-43 has PGRN-binding properties, coupled with what
is known about the effects of PGRN and GRN on nuclear-
cytoplasmic trafficking of certain proteins, one can envis-
age how dysfunction or dysregulation of PGRN might
contribute to abnormal compartmentalization of TDP-43
(Figure 5).
Conclusion
PGRN is a complex protein that has distinct functional
properties as an intact precursor protein compared to
GRN peptides derived from its proteolytic cleavage. In
peripheral tissues, it has been implicated in development,
maintenance, repair, inflammation and neoplasia. The
interactions of elastase, SLPI and PGRN leads to specula-
tion that PGRN may have pro- or anti-inflammatory prop-
erties depending upon the extent of regulated proteolysis
of PGRN and generation of pro-inflammatory GRN pep-
tides.Journal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
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Neuropathology of FTLD-U with PGRN mutations Figure 4
Neuropathology of FTLD-U with PGRN mutations. Gross cortical atrophy is visible in frontal and superior temporal lobes (A). 
In coronal sections (B), the lateral ventricle is dilated and the caudate nucleus is flat (arrow). Laminar spongiosis in the layer II 
of the cortical ribbon (C) is associated with TDP-43-positive neuronal cytoplasmic (D, arrows) and "lentiform" intranuclear 
inclusions (inset). Severe neuronal loss (D) in these regions is associated with microgliosis (E) and astrogliosis (F), shown by a 
microglial marker [ionized calcium-binding adapter molecule 1 (Iba-1)) and glial fibrillary acidic protein (GFAP) specific immu-
nohistochemistry, respectively.Journal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
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PGRN is expressed in the developing CNS, where its
growth promoting function has been suggested. In the
mature CNS immunohistochemical and in situ hybridiza-
tion studies have shown that certain populations of neu-
rons express PGRN. There is evidence that full-length
PGRN may function as a neuronal growth factor. In this
light, pathogenic PGRN mutations that lead to decreases
in functional PGRN may produce neurodegeneration in
FTLDU as a result of decreases in neurotrophic activity.
Microglia are the other major cell type that expresses
PGRN in the CNS. Trauma, infection and neurodegenera-
tion are all accompanied by increases in PGRN mRNA
expression. These results are consistent with the notion
that PGRN expression is directly or indirectly related to
microglial proliferation and activation, implicating PGRN
in neuroinflammation and potentially brain repair. The
role of altered PGRN in microglia in this regard needs fur-
ther investigation since some studies have suggested
trophic rather than toxic functions of microglia in specific
circumstances. Studies of microglia and the inflammatory
responses in PGRN mutation carriers and controls, as well
as in PGRN knock out mice will be useful in determining
Schematic model of nuclear trafficking of cyclin T1 and it alterations by PGRN and GRN Figure 5
Schematic model of nuclear trafficking of cyclin T1 and it alterations by PGRN and GRN. Cyclin T1 binds PGRN and some of 
its GRN derivatives when co-expressed in COS7 cells [91]. A) When cyclin T1 is expressed with full length PGRN, both pro-
teins are localized in the cytoplasm. B) In contrast, when expressed with the C-terminal GRN, CDE, cyclin T1 and GRN are 
found in the nucleus, enabling down-stream transcription elongation. Given the evidence that PGRN and GRN are associated 
with translocation of proteins such as cyclin T1 from cytoplasm to nucleus, it is tempting to hypothesize that PGRN might be 
involved in similar regulation of TDP-43 nuclear-cytoplasmic translocation. With decreased functional PGRN in FTLD-U asso-
ciated with PGRN mutations, TDP-43 translocation might be perturbed, leading to accumulation in the cytoplasm and formation 
of NCI.Journal of Neuroinflammation 2007, 4:7 http://www.jneuroinflammation.com/content/4/1/7
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not only the normal function of PGRN in the CNS, but
also its role in the pathogenesis of FTLDU.
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